Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

This publication has 33 references indexed in Scilit:

• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
  Cancer Research, 2004
• M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
  Cell Death & Differentiation, 2003
• Transcriptional regulation by calcium, calcineurin, and NFAT
  Genes & Development, 2003
• Inflammatory Mediators as Essential Elements in Bone Remodeling
  Calcified Tissue International, 2003
• Identification of TOR Signaling Complexes: More TORC for the Cell Growth Engine
  Cell, 2002
• Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin
  Molecular and Cellular Biology, 2002
• Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB
  Journal of Biological Chemistry, 2002
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
  Nature Medicine, 2002
• Immunosuppressant Use Without Bone Loss—Implications for Bone Loss After Transplantation
  Journal of Bone and Mineral Research, 2001
• The identification and characterization of expression of Pftaire‐1 , a novel Cdk family member, suggest its function in the mouse testis and nervous system
  Molecular Reproduction and Development, 1998